Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase

Leukemia

Volumn 23, Issue 6, 2009, Pages 1171-1174

  Huang, H ^a,a   Lai, X Y ^a   Tan, Y M ^a   Shi, J M ^a   Zhao, Y M ^a   Han, X Y ^a   Zheng, G F ^a   Zhu, X L ^a   Sun, J ^a   Zheng, Y L ^a   Wu, G Q ^a   He, J S ^a   Chen, S Y ^a   Jin, A Y ^a   Xie, W Z ^a   Ye, X J ^a   Cai, Z ^a   Lin, M F ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT FAILURE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA RELAPSE; MALE; MUCOSA INFLAMMATION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING;

EID: 67349153682     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.401     Document Type: Article

References (6)

1. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
2. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614-4617.
3. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969-2976.
4. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332-1339.
5. Chen J, Schmitt A, Giannopoulos K, Chen B, Rojewski M, Döhner H et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 2007; 31: 1133-1139.
6. Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105: 1135-1143.